Abstract:Background Subtyping schizophrenia can disentangle heterogeneity and help with treatment decision- making. However, current schizophrenia subtypes have not demonstrated adequate clinical utility, limited by sample size, suboptimal clustering methods, and choice of clustering input. Polygenic scores (PGS) reflect the genetic risk of phenotypes including comorbidities and are available before treatment, making them candidate clustering input. Methods We derived PGS for schizophrenia, autism spectrum disorder, bipolar disorder type-1, depression, and intelligence in 4,915 schizophrenia cases with register linkage. We randomly divided the sample into discovery and replication partitions and applied a novel clustering workflow on both: preprocessing PGS, feature extraction with uniform manifold approximation and projection (UMAP), and clustering with density-based spatial clustering of applications with noise (DBSCAN). After replication, we re-performed clustering on the entire sample and evaluated treatment-relevant variables of medication and hospitalization (extracted from registers) across clusters. Outcomes We identified five well-replicated PGS clusters. Cluster 1 (26% of entire sample) with generally lower PGS, had the least use of antipsychotics (including clozapine), and fewer outpatient visits. Cluster 2 (48%) with generally higher PGS, especially schizophrenia PGS, had more prescriptions of antipsychotics including clozapine and longer treatment with clozapine. Each featured by specific PGS, clusters 3 (high IQ-PGS, 11%), 4 (high ASD-PGS, 8%), 5 (high BIP-PGS, 7%) showed sub-threshold level significance in the corresponding phenotypic measures but did not differ significantly in the treatment-relevant variables. Solely categorizing the patients with SCZ-PGS did not generate any significant patterns in the phenotypic and treatment-relevant variables. Interpretation The results suggest that combinations of PGS of brain disorders and traits can provide clinically relevant clusters, offering a direction for future research on schizophrenia subtyping. Future replications in independent samples are required. The workflow can be generalized to other disorders and with mechanism-informed PGS. ### Competing Interest Statement The authors have declared no competing interest. ### Funding Statement PFS was supported by the Swedish Research Council (Vetenskapsradet, award D0886501), the Horizon 2020 Program of the European Union (COSYN, RIA Grant Agreement No. 610307), and US NIMH (U01 MH109528 and R01 MH077139). LY was supported by the US NIMH R01 MH123724 and MH124873, and the European Research Council (grant agreement ID: 101042183). KK was supported by the NIMH (MH123724) and the University of Manitoba. SY was supported by Karolinska Institutet. ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: The research procedures were approved by ethical committees at the Karolinska Institutet with written informed consent provided by the subjects. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes All data produced in the present work are contained in the manuscript and supplementary material

Use of multiple polygenic risk scores for distinguishing schizophrenia-spectrum disorder and affective psychosis categories in a first-episode sample; the EU-GEI study

Polygenic and Polyenvironment Interplay in Schizophrenia-Spectrum Disorder and Affective Psychosis; the EUGEI First Episode Study

Use of Schizophrenia and Bipolar Disorder Polygenic Risk Scores to Identify Psychotic Disorders

Polygenic risk scores mediating functioning outcomes through cognitive and clinical features in youth at family risk and controls

A Polygenic Risk Score Analysis of Psychosis Endophenotypes Across Brain Functional, Structural, and Cognitive Domains.

Distinguishing different psychiatric disorders using DDx-PRS

SCHIZOPHRENIA POLYGENIC RISK SCORE PREDICTS ANTIPSYCHOTIC TREATMENT RESPONSE IN PATIENTS WITH FIRST EPISODE PSYCHOSIS

Schizophrenia polygenic risk scores, clinical variables and genetic pathways as predictors of phenotypic traits of bipolar I disorder

Polygenic risk for schizophrenia and measured domains of cognition in individuals with psychosis and controls

Polygenic Risk Scores and Twin Concordance for Schizophrenia and Bipolar Disorder

Proof of concept: Molecular prediction of schizophrenia risk

Penetrance and Pleiotropy of Polygenic Risk Scores for Schizophrenia, Bipolar Disorder, and Depression Among Adults in the US Veterans Affairs Health Care System

Polygenic Burden Analysis of Longitudinal Clusters of Psychopathological Features in A Cross-Diagnostic Group of Individuals with Severe Mental Illness

The effect of polygenic risk score and childhood adversity on transdiagnostic symptom dimensions at first-episode psychosis: evidence for an affective pathway to psychosis

Association of schizophrenia polygenic risk score with data-driven cognitive subtypes: A six-year longitudinal study in patients, siblings and controls

Psychosis Endophenotypes: A Gene-Set-Specific Polygenic Risk Score Analysis.

Prediction of antipsychotics efficacy based on a polygenic risk score: a real-world cohort study

A Genome-wide Association Analysis of a Broad Psychosis Phenotype Identifies Three Loci for Further Investigation

Social disadvantage, linguistic distance, ethnic minority status and first-episode psychosis: results from the EU-GEI case-control study

Subtyping Schizophrenia Using Psychiatric Polygenic Scores

Risk Stratification for Bipolar Disorder Using Polygenic Risk Scores Among Young High-Risk Adults